-
Product Insights
Premature Ovarian Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Premature Ovarian Failure - Drugs In Development, 2023’, provides an overview of the Premature Ovarian Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Premature Ovarian Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2023’, provides an overview of the Female Hypoactive Sexual Desire Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) - Drugs In Development, 2023’, provides an overview of the Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Dysmenorrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Dysmenorrhea - Drugs In Development, 2023’, provides an overview of the Dysmenorrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dysmenorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ovarian Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Ovarian Disease - Drugs In Development, 2023’, provides an overview of the Ovarian Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Female Sexual Dysfunction – Drugs In Development, 2023
Global Markets Direct’s, ‘Female Sexual Dysfunction - Drugs In Development, 2023’, provides an overview of the Female Sexual Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Menopausal Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Menopausal Disorders - Drugs In Development, 2023’, provides an overview of the Menopausal Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Menopausal Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Female Contraceptives Market Report Overview The female contraceptives market sales across the 7MM was $7.8 billion in 2022. The market is expected to achieve a CAGR of less than 1% during 2022-2032. During the forecast period, sales of female contraceptives will increase in the UK due to the rising female population. Conversely, sales in France, Germany, Italy, and Spain markets will decrease owing to the declining female population. Female Contraceptives Market Outlook, 2022-2032 ($ Billion) Buy the Full Report to...
-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...